|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBXL12 |
Gene summary for FBXL12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBXL12 | Gene ID | 54850 |
| Gene name | F-box and leucine rich repeat protein 12 | |
| Gene Alias | Fbl12 | |
| Cytomap | 19p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000086 | UniProtAcc | Q9NXK8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54850 | FBXL12 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.19e-04 | 2.02e-01 | -0.1954 |
| 54850 | FBXL12 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.98e-02 | 1.78e-01 | -0.1464 |
| 54850 | FBXL12 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.03e-15 | 6.82e-01 | 0.281 |
| 54850 | FBXL12 | LZE4T | Human | Esophagus | ESCC | 1.56e-08 | 3.01e-01 | 0.0811 |
| 54850 | FBXL12 | LZE7T | Human | Esophagus | ESCC | 5.08e-05 | 4.56e-01 | 0.0667 |
| 54850 | FBXL12 | LZE8T | Human | Esophagus | ESCC | 1.53e-05 | 1.54e-01 | 0.067 |
| 54850 | FBXL12 | LZE24T | Human | Esophagus | ESCC | 1.28e-19 | 5.60e-01 | 0.0596 |
| 54850 | FBXL12 | P1T-E | Human | Esophagus | ESCC | 7.24e-06 | 5.06e-01 | 0.0875 |
| 54850 | FBXL12 | P2T-E | Human | Esophagus | ESCC | 2.07e-17 | 2.43e-01 | 0.1177 |
| 54850 | FBXL12 | P4T-E | Human | Esophagus | ESCC | 7.40e-25 | 6.30e-01 | 0.1323 |
| 54850 | FBXL12 | P5T-E | Human | Esophagus | ESCC | 1.45e-17 | 3.48e-01 | 0.1327 |
| 54850 | FBXL12 | P8T-E | Human | Esophagus | ESCC | 2.25e-35 | 5.79e-01 | 0.0889 |
| 54850 | FBXL12 | P9T-E | Human | Esophagus | ESCC | 7.42e-21 | 4.78e-01 | 0.1131 |
| 54850 | FBXL12 | P10T-E | Human | Esophagus | ESCC | 3.49e-27 | 4.73e-01 | 0.116 |
| 54850 | FBXL12 | P11T-E | Human | Esophagus | ESCC | 7.05e-15 | 6.98e-01 | 0.1426 |
| 54850 | FBXL12 | P12T-E | Human | Esophagus | ESCC | 3.30e-30 | 7.35e-01 | 0.1122 |
| 54850 | FBXL12 | P15T-E | Human | Esophagus | ESCC | 7.37e-22 | 4.64e-01 | 0.1149 |
| 54850 | FBXL12 | P16T-E | Human | Esophagus | ESCC | 1.35e-18 | 2.36e-01 | 0.1153 |
| 54850 | FBXL12 | P20T-E | Human | Esophagus | ESCC | 5.80e-10 | 2.89e-01 | 0.1124 |
| 54850 | FBXL12 | P21T-E | Human | Esophagus | ESCC | 2.20e-17 | 3.23e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
| GO:0043161 | Colorectum | AD | proteasome-mediated ubiquitin-dependent protein catabolic process | 141/3918 | 412/18723 | 1.77e-10 | 1.68e-08 | 141 |
| GO:0007623 | Colorectum | AD | circadian rhythm | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
| GO:0048511 | Colorectum | AD | rhythmic process | 94/3918 | 298/18723 | 1.00e-05 | 2.34e-04 | 94 |
| GO:0042752 | Colorectum | AD | regulation of circadian rhythm | 40/3918 | 121/18723 | 1.24e-03 | 1.09e-02 | 40 |
| GO:00104982 | Colorectum | MSS | proteasomal protein catabolic process | 157/3467 | 490/18723 | 2.39e-13 | 5.25e-11 | 157 |
| GO:00431612 | Colorectum | MSS | proteasome-mediated ubiquitin-dependent protein catabolic process | 127/3467 | 412/18723 | 7.70e-10 | 6.32e-08 | 127 |
| GO:00076232 | Colorectum | MSS | circadian rhythm | 69/3467 | 210/18723 | 4.22e-07 | 1.67e-05 | 69 |
| GO:00485112 | Colorectum | MSS | rhythmic process | 89/3467 | 298/18723 | 1.17e-06 | 3.96e-05 | 89 |
| GO:00427522 | Colorectum | MSS | regulation of circadian rhythm | 38/3467 | 121/18723 | 4.33e-04 | 5.23e-03 | 38 |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
| GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
| GO:000941611 | Esophagus | ESCC | response to light stimulus | 183/8552 | 320/18723 | 2.03e-05 | 1.76e-04 | 183 |
| GO:004851118 | Esophagus | ESCC | rhythmic process | 164/8552 | 298/18723 | 6.80e-04 | 3.57e-03 | 164 |
| GO:000762319 | Esophagus | ESCC | circadian rhythm | 119/8552 | 210/18723 | 8.47e-04 | 4.36e-03 | 119 |
| GO:00311461 | Esophagus | ESCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBXL12 | SNV | Missense_Mutation | novel | c.722N>G | p.Ser241Cys | p.S241C | Q9NXK8 | protein_coding | deleterious(0) | benign(0.021) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FBXL12 | SNV | Missense_Mutation | novel | c.908T>G | p.Leu303Arg | p.L303R | Q9NXK8 | protein_coding | tolerated(0.62) | possibly_damaging(0.634) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| FBXL12 | SNV | Missense_Mutation | novel | c.300G>T | p.Lys100Asn | p.K100N | Q9NXK8 | protein_coding | deleterious(0.01) | possibly_damaging(0.535) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FBXL12 | SNV | Missense_Mutation | novel | c.529G>C | p.Ala177Pro | p.A177P | Q9NXK8 | protein_coding | tolerated(0.22) | possibly_damaging(0.55) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| FBXL12 | SNV | Missense_Mutation | novel | c.671N>T | p.Ser224Ile | p.S224I | Q9NXK8 | protein_coding | deleterious(0.01) | benign(0.307) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FBXL12 | SNV | Missense_Mutation | novel | c.284G>T | p.Arg95Ile | p.R95I | Q9NXK8 | protein_coding | tolerated(0.08) | benign(0.138) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| FBXL12 | SNV | Missense_Mutation | rs138149906 | c.317N>A | p.Arg106His | p.R106H | Q9NXK8 | protein_coding | tolerated(0.33) | benign(0.003) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| FBXL12 | SNV | Missense_Mutation | novel | c.362G>A | p.Ser121Asn | p.S121N | Q9NXK8 | protein_coding | tolerated(0.31) | benign(0.263) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FBXL12 | SNV | Missense_Mutation | rs375844904 | c.683N>A | p.Arg228Gln | p.R228Q | Q9NXK8 | protein_coding | tolerated(0.06) | benign(0.012) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FBXL12 | SNV | Missense_Mutation | novel | c.243C>A | p.Phe81Leu | p.F81L | Q9NXK8 | protein_coding | tolerated(0.69) | benign(0) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |